Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer: Results from the GeparQuattro study (GBG 40).
G. Von Minckwitz
No relevant relationships to disclose
S. Darb-Esfahani
No relevant relationships to disclose
S. Loibl
No relevant relationships to disclose
J. B. Huober
Consultant or Advisory Role - GlaxoSmithKline; Roche; Sanofi
Honoraria - Sanofi
Research Funding - GlaxoSmithKline
H. Tesch
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Roche; Sanofi
Honoraria - GlaxoSmithKline; Novartis; Roche; Sanofi
C. Solbach
No relevant relationships to disclose
F. Holms
No relevant relationships to disclose
H. Eidtmann
No relevant relationships to disclose
K. Diedrich
No relevant relationships to disclose
M. Just
No relevant relationships to disclose
M. Clemens
No relevant relationships to disclose
C. Hanusch
No relevant relationships to disclose
I. Schrader
No relevant relationships to disclose
S. Henschen
No relevant relationships to disclose
G. Hoffmann
No relevant relationships to disclose
K. Tiemann
No relevant relationships to disclose
K. Diebold
No relevant relationships to disclose
M. Untch
No relevant relationships to disclose
C. Denkert
No relevant relationships to disclose